Akrikhin continues to strengthen its internal organization and focus on the development of key business segments. To this end, the company has undergone personnel changes: a new commercial director and vice president for generic drugs have been appointed.
The transformation of the business reality of the pharmaceutical market, and active development of the commercial sector and sales channels, specifically e-commerce, require the most advanced practices and management decisions. At the end of 2022, a new commercial director, Alexander Sokolov, was appointed to implement the strategic plans of Akrikhin. In his position, he reports to the CEO Denis Chetverikov.
Alexander is responsible for implementing the company’s commercial strategy; improving the customer relations model to enhance efficient collaboration in the face of market changes; further strengthening the traditional sales channels and developing new promising digital channels, creating modern integration solutions in data management (Business Intelligence) to improve the quality of product supply planning; as well as strengthening the company’s work in the important area of fulfilling public contracts and expanding the availability of popular and high-quality pharmaceuticals nationwide.
Alexander graduated with honours from the Ivanovo State Medical Academy, and then received an additional qualification under the Manage Mentor program at one of the most famous universities in the world, Harvard. Alexander’s career in the pharmaceutical industry started in 2003. For the past 8 years, he led the sales department and the commercial department at Teva. In addition, Alexander has professional experience in senior commercial positions with other international companies
Another appointment in the company is due to the fact that in 2023 Akrikhin’s generics area has been separated into an independent business unit, a Generics Sales and Marketing division. Thanks to these changes, the company strengthens its focus on the business of generic drugs (the INN-Akrikhin portfolio), creates extra resources for their promotion via all sales channels, including pharmacy chains, e-commerce and public contracts, as well as creates opportunities to ramp up the production of the portfolio products at the local manufacturing site in Staraya Kupavna.
The management of the business unit has been taken over by Lidiya Choborovskaya, Vice President for Generic Drugs, reporting directly to the CEO Denis Chetverikov.
Lidiya graduated from the Chelyabinsk State Medical Academy, majoring in Anaesthesiology and Resuscitation. She has many years of experience in the pharmaceutical industry and has worked her way up from a medical representative to a commercial director, worked as part of management teams at Krka, Teva, Akrikhin, Besins Healthcare RUS.